Cancer cells block T-cell activation, but new therapies restore immune defenses

Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment. Restoring balance through PGE2 inhibition and IFN-I enhancement could renew immune defenses and improve immunotherapy outcomes.

Tulane study finds potential treatment for eosinophilic esophagitis

A new study from Tulane University has identified a new treatment for a chronic immune system disease that can prevent children from eating.

July 31, 2023

The Era of AI – A Renaissance or Revolution for Healthcare?

Robert L. Gordon III, Sr. Strategic Leader for AI and Digital Innovation, DSS Inc. The advent of Artificial Intelligence (AI) portends a potentially monumental shift

May 15, 2024

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based

June 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.